Dover Advisors LLC lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 35.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,580 shares of the medical instruments supplier's stock after selling 1,930 shares during the quarter. Dover Advisors LLC's holdings in Becton, Dickinson and Company were worth $820,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at about $25,000. Sierra Ocean LLC bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at about $29,000. REAP Financial Group LLC increased its holdings in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Picton Mahoney Asset Management increased its holdings in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after purchasing an additional 54 shares during the last quarter. Finally, Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company in the first quarter valued at about $34,000. Institutional investors own 86.97% of the company's stock.
Wall Street Analyst Weigh In
BDX has been the subject of a number of research analyst reports. Wall Street Zen cut Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Wells Fargo & Company cut Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. Raymond James cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Piper Sandler cut Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Finally, Citigroup cut Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their target price for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $219.22.
Get Our Latest Analysis on Becton, Dickinson and Company
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president now directly owns 4,575 shares in the company, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,104 shares of company stock worth $399,675. Company insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Stock Down 1.4%
NYSE BDX traded down $2.40 during trading hours on Friday, hitting $172.06. 2,276,369 shares of the company traded hands, compared to its average volume of 1,975,669. The business's 50-day moving average is $183.03 and its 200-day moving average is $213.01. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The stock has a market capitalization of $49.31 billion, a price-to-earnings ratio of 28.58, a P/E/G ratio of 1.63 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The firm had revenue of $5.27 billion during the quarter, compared to analysts' expectations of $5.35 billion. During the same period in the prior year, the firm posted $3.17 earnings per share. The business's quarterly revenue was up 4.5% compared to the same quarter last year. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.42%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 79.39%.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
